The global market for viral vectors and plasmid DNA manufacturing has reached a valuation of US $6320.3 million in 2024 and is expected to witness a remarkable CAGR of 22.21% from 2025 to 2033. This growth is driven by increased investments in gene therapy research and the rising demand for innovative treatment modalities in gene therapy, cell therapy, antisense & RNAi therapy, and vaccinology.

Recent advancements and regulatory approvals, such as the FDA’s recent endorsement of Kymriah for a new therapeutic indication, underscore the expanding utility and safety considerations of gene therapies. The market is experiencing a significant surge due to the transformative potential of gene therapies to treat a spectrum of genetic and acquired diseases, providing targeted, and precise interventions tailored to individual patient needs.

Viral vector types like AAV are gaining prominence due to their favorable safety profile and effectiveness in mediating long-term gene expression. The AAV vector's success in clinical trials, particularly for treatments targeting spinal muscular atrophy and inherited retinal disorders, has solidified its position as a leader in gene therapy applications.

The sector of vaccinology leads the applications in gene therapy, propelled by the urgent global response to the COVID-19 pandemic. This response highlighted the critical role of gene-based vaccines in controlling infectious diseases, with significant public and private funding accelerating vaccine development.

North America is projected to lead the market growth during the forecast period, backed by a robust R&D ecosystem and supportive regulatory environment. The region's proactive approach to gene therapy approvals has fostered innovation and rapid commercialization of new therapies.

"The viral vectors and plasmid DNA manufacturing market is a beacon of hope in the pursuit of curing intractable diseases through gene therapies. Our commitment to advancing this field is unwavering, as demonstrated by substantial investments in R&D and strategic collaborations to enhance treatment outcomes," said a spokesperson for Lonza Group, one of the market leaders.

As the market continues to evolve, competition among key players like Lonza is intensifying, with companies increasingly investing in novel technologies and expanding production capacities to meet global demand.